New melanoma cancer drug in development shows promise
University of Oxford and Immunocore Ltd have investigated Tebentafusp, a new anti-tumor immune response drug for patients with metastatic melanoma
University of Oxford and Immunocore Ltd have investigated Tebentafusp, a new anti-tumor immune response drug for patients with metastatic melanoma
Development Fund winners from the Freeman group are investigating newly discovered proteins and their potential as targets for new cancer treatments
A new study from the UK Coronavirus Cancer Monitoring Project (UKCCMP) has investigated which cancer patients may be more susceptible to the impacts of coronavirus
Research shows how IL-22 interacts with KRAS mutant tumours to promote excessive growth in colorectal cancer
The new Oxford Lymphoid Disorder Study Group, chaired by Dr Graham Collins, will be launched this September in Blood Cancer Awareness Month
New research will help GPs to identify the signs they should look for to swiftly diagnose cancer in people with unexpected weight loss
A new study has found that the allelic appearance of the TP53 gene has great impact on development of severe types of blood cancer
Cancer research UK Oxford Centre Development Fund Awardees Ysobel Baker and Tom Brown investigate the potential of DNA and RNA molecules as precision cancer treatments
You can keep in touch in a number of ways: